| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 76951 |
CAS: 1869126-64-6， Azido-PEG4-Val-Cit-PAB-MMAE |
101 |
WYQ |
2024-12-19 |
| 76952 |
cas:2353409-54-6 ， Mal-amido-PEG8-Val-Gly，ADC定制 |
116 |
wyh |
2024-12-19 |
| 76953 |
Azido-PEG4-Val-Ala-PAB-PNP |
116 |
zyl |
2024-12-19 |
| 76954 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
92 |
h |
2024-12-19 |
| 76955 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid，ADC定制 |
97 |
wyh |
2024-12-19 |
| 76956 |
CAS: 1343476-44-7，Val-Ala-PAB-OH |
91 |
WYQ |
2024-12-19 |
| 76957 |
MC-PBD， ADC试剂 |
103 |
kx |
2024-12-19 |
| 76958 |
Mal-Val-Ala-PAB的介绍 |
107 |
zyl |
2024-12-19 |
| 76959 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
94 |
h |
2024-12-19 |
| 76960 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
97 |
WYQ |
2024-12-19 |
| 76961 |
Arm-DOTA-B72.3 |
91 |
h |
2024-12-19 |
| 76962 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
109 |
zyl |
2024-12-19 |
| 76963 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
147 |
h |
2024-12-19 |
| 76964 |
1801838-28-7，Mc-vc-PAB-SN38，化合物MC-VC-PAB-SN38 |
102 |
kx |
2024-12-19 |
| 76965 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
100 |
h |
2024-12-19 |
| 76966 |
CAS: 863971-17-9，MC-Val-Cit-PAB-MMAF |
121 |
WYQ |
2024-12-19 |
| 76967 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
135 |
zyl |
2024-12-19 |
| 76968 |
DBCO-PEG4-vc-PAB-MMAE， ADC试剂 |
124 |
kx |
2024-12-19 |
| 76969 |
1884578-00-0，Boc-PEG4-Val-Ala-PAB-PNP，ADC定制 |
126 |
wyh |
2024-12-19 |
| 76970 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
90 |
h |
2024-12-19 |
| 76971 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
111 |
h |
2024-12-19 |
| 76972 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB，ADC定制 |
122 |
wyh |
2024-12-19 |
| 76973 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
101 |
h |
2024-12-19 |
| 76974 |
Azido-PEG4-MMAE，抗体药物偶联物（ADCs） |
136 |
WYQ |
2024-12-19 |
| 76975 |
1626359-62-3，SPDB-DM4， ADC试剂 |
91 |
kx |
2024-12-19 |
| 76976 |
Acid-PEG4-Val-Cit-PAB-MMAE，包含PEG链和MMAE等部分 |
104 |
WYQ |
2024-12-19 |
| 76977 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，ADC定制 |
119 |
wyh |
2024-12-19 |
| 76978 |
DOTA-(D)Phe(1)-Tyr(3) |
101 |
h |
2024-12-19 |
| 76979 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
140 |
zyl |
2024-12-19 |
| 76980 |
FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne |
139 |
WYQ |
2024-12-19 |
| 76981 |
DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 |
97 |
h |
2024-12-19 |
| 76982 |
CAS: 2762518-86-3 ，NHS ester-PEG4-Val-Cit-PAB-MMAE |
107 |
WYQ |
2024-12-19 |
| 76983 |
cas:2873452-49-2 ； MC-EVCit-PAB-MMAE，ADC定制 |
122 |
wyh |
2024-12-19 |
| 76984 |
CAS: 2762519-08-2 endo-BCN-PEG4-Val-Cit-PAB-MMAE，内末端二苯卡宾吡啶甲酸乙酯聚乙二醇4个单元赖氨酸缬氨酸丙氨酸天冬氨酸 |
140 |
WYQ |
2024-12-19 |
| 76985 |
cas:863971-24-8，Mc-MMAE ，马来酰亚胺基己酰-单甲基澳瑞他汀 E |
178 |
kx |
2024-12-19 |
| 76986 |
DOTA-(AEEA)2-BN DOTA-(AEEA)2-铃蟾肽 |
106 |
h |
2024-12-19 |
| 76987 |
cas:2259318-55-1 ， DBCO-(PEG2-VC-PAB-MMAE)2，ADC定制 |
111 |
wyh |
2024-12-19 |
| 76988 |
cas:1394238-91-5 Fmoc-Val-Ala-PAB |
133 |
zyl |
2024-12-19 |
| 76989 |
CAS: 2285373-84-2 Ethyl (S)-1-((1-((4-((((4-nitrophenoxy)carbonyl) oxy)methyl)phenyl)amino)-1-oxo-5-ureidopenta n-2-yl)carbamoyl)cyclobutane-1-carboxylate |
158 |
WYQ |
2024-12-19 |
| 76990 |
Azido-Phenyl-Amido-SS-Sulfo-NHS Ester， ADC试剂 |
111 |
kx |
2024-12-19 |
| 76991 |
DOTA-βala-K-NOTA-BBN(7-14)NH2 |
122 |
h |
2024-12-19 |
| 76992 |
DBCO-PEG3-acetic-Val-Cit-PAB，主要用于合成抗体偶联药物（ADC） |
108 |
WYQ |
2024-12-19 |
| 76993 |
Mal-PEG4-Val-Ala-PAB-PNP，ADC定制 |
87 |
wyh |
2024-12-19 |
| 76994 |
cas:330970-70-2 Alloc-Val-Ala-OH |
107 |
zyl |
2024-12-19 |
| 76995 |
DOTA-somatostatin receptor analogs DOTA生长抑素受体类似物 |
83 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询